Key facts
- This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
- 9 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 18 Aug 2026, 18:02.
Neil Kumar - 16 Aug 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- BBIO
- Reported as of
- 16 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Aug 2026, 18:02:32 UTC
- Prior SEC filing
- 18 Jun 2026
- Next SEC filing
- 20 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Will Solis, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 18 Aug 2026.
Change
- Previous filing in this sequence was filed on 18 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001742485
Primary reporting owner
Kumar Neil
- Relationship
- Chief Executive Officer, Director
- Address
- C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
- Signature
- /s/ Will Solis, Attorney-in-Fact
- Signature date
- 18 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +33,544
- Change %
- +14%
- Price
- Shares after
- 276,871
- Date
- 16 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +19,599
- Change %
- +7.1%
- Price
- Shares after
- 296,470
- Date
- 16 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +11,554
- Change %
- +3.9%
- Price
- Shares after
- 308,024
- Date
- 16 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +6,520
- Change %
- +2.1%
- Price
- Shares after
- 314,544
- Date
- 16 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -36,237
- Change %
- -12%
- Price
- $79.86*
- Shares after
- 278,307
- Date
- 16 Aug 2026
- Ownership
- Direct
- Footnotes
- F2
BBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 515,686
- Date
- 16 Aug 2026
- Ownership
- By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
- Footnotes
- F3
BBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,568,447
- Date
- 16 Aug 2026
- Ownership
- By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
- Footnotes
- F3, F4
BBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 750,000
- Date
- 16 Aug 2026
- Ownership
- By NK 2026 GRAT
- Footnotes
- F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -33,544
- Change %
- -33%
- Price
- $0.000000*
- Shares after
- 67,088
- Date
- 16 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 33,544
- Exercise price
- Footnotes
- F1, F6
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -19,599
- Change %
- -14%
- Price
- $0.000000*
- Shares after
- 117,596
- Date
- 16 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,599
- Exercise price
- Footnotes
- F1, F7
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -11,554
- Change %
- -9.1%
- Price
- $0.000000*
- Shares after
- 115,538
- Date
- 16 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,554
- Exercise price
- Footnotes
- F1, F8
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -6,520
- Change %
- -6.7%
- Price
- $0.000000*
- Shares after
- 91,274
- Date
- 16 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,520
- Exercise price
- Footnotes
- F1, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,217 shares of Common Stock underlying the Reporting Person's RSUs.
Footnote F3
The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Footnote F4
Reflects a prior transfer of 750,000 shares of Common Stock from the Kumar Haldea Revocable Trust to the NK 2026 GRAT. The transfer constituted only a change in form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
Footnote F5
These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
Footnote F6
The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Footnote F7
The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Footnote F8
The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Footnote F9
The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.